Document is current

Article History

Received: 8 June 2022

Accepted: 9 September 2022

First Online: 17 September 2022

Declarations

:

: GL declares to be a consultant for Allergan, Almirall, Biogen, Novartis Sanofi, Merck Serono, Bristol, Ipsen, and Bristol Celgene. VBM has received funding for research support and speaker honoraria from Novartis, Roche, Biogen, Teva, Almirall, Sanofi-Genzyme, Merck, Bayer, and Mylan. SB received speaker honoraria and/or advisory board fee from Novartis, Sanofi Genzyme, Merck-Serono, Brystol-Meyers, Biogen-Idec, Viatris, and Roche. AG received personal compensations for speaking or consultancy from Biogen, Bristol Myers Squibb, Merck-Serono, Mylan, Novartis, Roche, Sanofi-Genzyme, and Teva. GTM received personal compensations from Serono, Biogen, Novartis, Roche, and TEVA for public speaking and advisory boards. FS received public speaking honoraria from Alexion, Argenx, Biogen, Mylan, Novartis, Roche, Sanofi, and Teva; he also received compensation for advisory boards or consultation fees from Alexion, Almirall, Argenx, Avexis, Biogen, Forward Pharma, Lexeo Therapeutics, Merk, Novartis, Novatek, Roche, Sanofi, and Takeda. MB declares fees from Biogen, Sanofi Genzyme, Roche, and Novartis. DM, GS, SC, ES, and LMEG declare no competing interests. MB, LM, and RT declare to be Novartis employees.

: Our study did not require an ethical board approval because no patients were actively involved.

: Not applicable.